RGD Reference Report - The soluble form of the receptor of advanced glycation endproducts increases after bariatric surgery in morbid obesity. - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

The soluble form of the receptor of advanced glycation endproducts increases after bariatric surgery in morbid obesity.

Authors: Brix, JM  Hollerl, F  Kopp, HP  Schernthaner, GH  Schernthaner, G 
Citation: Brix JM, etal., Int J Obes (Lond). 2012 Nov;36(11):1412-7. doi: 10.1038/ijo.2012.107. Epub 2012 Jul 17.
RGD ID: 7243249
Pubmed: PMID:22828946   (View Abstract at PubMed)
DOI: DOI:10.1038/ijo.2012.107   (Journal Full-text)

OBJECTIVE: The increased cardiovascular (CV) disease risk in patients with morbid obesity (MO) cannot be fully explained by traditional CV risk factors. Activation of the receptor of Advanced Glycation Endproducts (RAGE) leads to inflammation via the NF kappabeta (nuclear factor kappabeta) pathway. The soluble form of RAGE (sRAGE), which is present in plasma, can bind to ligands of RAGE and avoids interaction of RAGE with proinflammatory ligands. We investigated sRAGE levels in patients with MO and compared them with healthy lean controls (CO), before and after bariatric surgery. DESIGN: We conducted a cross-sectional study and a 24-month longitudinal study. SUBJECTS: We included 85 patients (mean age: 41 +/- 12 years; mean body mass index (BMI): 45.4 +/- 7.9 kg m(-2)) with MO in comparison with 40 CO (mean age: 42 +/- 13 years; mean BMI: 26.0 +/- 5.5 kg m(-2)). All patients were investigated before and 2 years after bariatric surgery. Apart from weight and CV risk markers (blood pressure, lipids), a glucose tolerance test (75 g), renal and inflammation parameters were assessed. sRAGE levels were assessed by a commercial ELISA. To investigate the associations of the observed reductions of values, delta (Delta) of parameters were calculated. RESULTS: Patients with MO had significant lower sRAGE levels than CO: 1010 +/- 514 vs 1501 +/- 674 pg ml(-1); P<0.001. In the longitudinal study, sRAGE levels increased significantly after bariatric surgery from 1010 +/- 514 to 1261 +/- 710 pg ml(-1); P=0.008. In the correlation analysis, DeltasRAGE levels were associated with Delta1-h and Delta2-h postprandial glucose, Deltafasting insulin, Delta2-h postprandial insulin, DeltaHOMA (homeostatic model assessment)-insulin resistance (DeltaHOMA-IR), Deltagamma-glutamyl transferase and Deltatriglycerides. In a multivariate model, Delta1-h and Delta2-h postprandial glucose, Delta2-h postprandial insulin and DeltaHOMA-IR predicted DeltasRAGE. CONCLUSION: Patients with MO have significantly lower sRAGE levels compared with non-obese CO, but sRAGE levels increase significantly after weight loss induced by bariatric surgery. As high sRAGE levels inhibit the activation of inflammatory pathways, our results might help understand the beneficial effects of bariatric surgery regarding CV morbidity and mortality.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
morbid obesity treatmentIDA 7243249 RGD 
morbid obesity treatmentISOAGER (Homo sapiens)7243249; 7243249 RGD 

Objects Annotated

Genes (Rattus norvegicus)
Ager  (advanced glycosylation end product-specific receptor)

Genes (Mus musculus)
Ager  (advanced glycosylation end product-specific receptor)

Genes (Homo sapiens)
AGER  (advanced glycosylation end-product specific receptor)


Additional Information